04.02.2014 • NewsDede WillamsCMIEU

EU Fines Flexible Foam Producers for Price Fixing

In its latest trust-busting move, the European Commission has closed a case dating from 2010, fining three manufacturers of flexible polyurethane foam €114 million for price fixing.
The Commission said four companies had founded a cartel aimed at passing on raw material price increases for bulk chemicals to customers and avoiding aggressive price competition among themselves.

Four players, including Luxembourg-based Vita; Carpenter of Richmond, Virginia; Belgium's Recticel and Austria's Eurofoam - the latter a joint venture of Recticel and Austrian Greiner Holding - were deemed to have fixed prices of various types of PU foam in 10 EU member states.

Whistleblower Vita's fine, which would have totaled €61.7m, was excused. In exchange for their cooperation, Eurofoam and its partners had their fines reduced by 50% to a total of €39.1m. Carpenter paid the highest, fine, of €75 million.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.